鸟枪弹样脉络膜视网膜病变全身皮质类固醇免疫调节治疗的长期疗效。
Long-term outcomes of systemic corticosteroid-sparing immunomodulatory therapy for Birdshot Retinochoroidopathy.
机构信息
Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham, Massachusetts, USA.
Ocular Immunology and Uveitis Foundation , Weston, Massachusetts, USA.
出版信息
Ocul Immunol Inflamm. 2020 Aug 17;28(6):966-974. doi: 10.1080/09273948.2019.1641610. Epub 2019 Sep 30.
PURPOSE
To report the visual prognosis, electroretinography (ERG) and perimetry outcomes of systemic corticosteroid-sparing immunomodulatory treatment (IMT) for birdshot retinochoroidopathy (BSRC).
METHODS
Retrospective non-comparative case series of 132 patients (264 eyes) with BSRC treated with IMT from Massachusetts Eye Research and Surgery Institution.
RESULTS
The average follow-up time was 60.1 months. After one year on IMT, 39.4% showed no clinically active inflammation. After 5 years of IMT, 78.0% had no signs of clinical inflammation. No significant differences were observed on best-corrected visual acuity (BCVA), ERG parameters, and perimetry parameters between baseline and subsequent visits on IMT.
CONCLUSION
Long-term systemic corticosteroid-sparing IMT was associated with a low rate of BSRC disease exacerbation. While differences were seen on testing parameters, they were not consistent trends and difference were attributed to variability of testing or fluctuation of inflammation that may be expected in the course of the disease.
目的
报告球后型类肉瘤病（BSRC）全身皮质类固醇免疫调节治疗（IMT）的视力预后、视网膜电图（ERG）和视野检查结果。
方法
回顾性非对照病例系列研究，来自马萨诸塞州眼科学研究与手术机构的 132 名（264 只眼）BSRC 患者接受 IMT 治疗。
结果
平均随访时间为 60.1 个月。IMT 治疗 1 年后，39.4%的患者无临床活动性炎症。IMT 治疗 5 年后，78.0%的患者无临床炎症迹象。IMT 期间，最佳矫正视力（BCVA）、ERG 参数和视野检查参数在基线和后续随访时无显著差异。
结论
长期全身皮质类固醇免疫调节治疗与 BSRC 疾病恶化率低相关。尽管在检测参数上存在差异，但这些差异并非一致趋势，差异归因于疾病过程中预期的检测变异性或炎症波动。
Zotero 插件